Eris Lifesciences' Q2 FY26 investor presentation shows 10% Q2 DBF revenue growth, 11% H1 growth, margin expansion to ~37.6% in Q2 and ~37.3% in H1, and RHI cartridge tailwinds in H2, with gSaxenda delay and price-increase pace noted.